Pancreatic ductal adenocarcinoma (PDAC) ubiquitination profiling reveals specific prognostic and theranostic markers.

The project was aimed at identifying diGlycine (diGly) conjugated peptides obtained from sixty PDACs' patients' derived xenografs (PDXs) then to identify potential diGLy profiles that could be used as prognosis markers of the aggressiveness of the tumour and overall survival of patients as well as theranostic makers able to predict tumour sensitivity to the different chemotherapeutic drugs commonly used to treat this form of cancer.